DMTS

Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey

Retrieved on: 
Thursday, February 22, 2024

Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.

Key Points: 
  • Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.
  • Analysis from 75 high-prescribing U.S. neurologists reveals the potential reasons behind the even slower-than-expected adoption of Leqembi for treatment of early AD.
  • Six months after the full commercial launch of Leqembi, few surveyed neurologists consider Leqembi to be a significant medical advance over other historical AD treatments.
  • For all these reasons, Spherix will continue tracking neurologists’ attitudes and use of DMTs in AD well into the future.

Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer's Disease, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, March 5, 2024

TORONTO, March 5, 2024 /PRNewswire-PRWeb/ -- The availability of disease-modifying treatments (DMTs) for early symptomatic Alzheimer's disease (AD) has greatly increased the need for clinical AD biomarker testing, which is helpful for determining whether cognitive impairment is caused by AD brain pathology or some other condition. Biomarker evidence of amyloid pathology is essential before the initiation of AD DMTs. This webinar will review the types of AD biomarker tests that are clinically available, including cerebrospinal fluid (CSF) biomarkers, amyloid positron emission tomography (PET) and AD blood tests.

Key Points: 
  • In this free webinar, learn about different Alzheimer's disease (AD) biomarker testing modalities, and the particular promise of high-performance AD blood tests.
  • Attendees will also learn about the variability in the diagnostic performance of AD blood tests and how performance affects the clinical use of tests.
  • This webinar will review the types of AD biomarker tests that are clinically available, including cerebrospinal fluid (CSF) biomarkers, amyloid positron emission tomography (PET) and AD blood tests.
  • Register for this webinar to learn more about different AD biomarker testing modalities, and the particular promise of high-performance AD blood tests.

Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights

Retrieved on: 
Friday, February 16, 2024

Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.

Key Points: 
  • Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.
  • Further, critical to the success of future gene therapies and DMTs is the identification of biomarkers associated with PD.
  • This underscores the importance of manufacturers engaging with healthcare professionals to provide insights into emerging therapies and MOAs.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Retrieved on: 
Wednesday, January 31, 2024

53 SIX Swiss Exchange Listing Rules

Key Points: 
  • 53 SIX Swiss Exchange Listing Rules
    Basel, January 31, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko® (natalizumab) in Germany from February 1.
  • Developed by Polpharma Biologics, Tyruko® is the first and only biosimilar to treat RRMS.
  • Rebecca Guntern, President Europe, Sandoz, said: “Early treatment with disease-modifying therapies can have a significant impact on people living with multiple sclerosis and their potential future disabilities.
  • Through an exclusive global license, Sandoz has the rights to commercialize and distribute it in all markets.

TOYO Corporation Acquires Leading European Dynamometer Manufacturer Rototest

Retrieved on: 
Thursday, November 30, 2023

TOYO Corporation (TOYO), a leading provider of advanced measurement solutions and Rototest® International AB (Rototest), a global innovator in the development of hub-coupled powertrain dynamometers, today announced that TOYO has acquired Rototest on November 30, 2023, Japan time.

Key Points: 
  • TOYO Corporation (TOYO), a leading provider of advanced measurement solutions and Rototest® International AB (Rototest), a global innovator in the development of hub-coupled powertrain dynamometers, today announced that TOYO has acquired Rototest on November 30, 2023, Japan time.
  • Henceforth, Rototest, headquartered in Rönninge, Sweden, will operate as a subsidiary of TOYO.
  • Christian Engström, Rototest's CEO, expressed, "TOYO acquiring Rototest marks a significant milestone for the company.
  • With TOYO, Rototest is poised to enhance its ability to provide innovative automotive test solutions to an even broader array of the world's leading manufacturers."

EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation

Retrieved on: 
Tuesday, October 10, 2023

These data were presented at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy.

Key Points: 
  • These data were presented at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy.
  • In a separate study out of Latin America, data was analyzed from 1,421 patients who received at least one course of cladribine tablets.
  • Over time, an increasing trend in treatment initiation among treatment-naïve patients was observed, suggesting an advantage of early utilization of cladribine treatment.
  • As well in both studies, very few patients receiving cladribine tablets switched to other therapies.

Merck Presents New MAVENCLAD® (Cladribine Tablets) Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation

Retrieved on: 
Tuesday, October 10, 2023

These data were presented at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy.

Key Points: 
  • These data were presented at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy.
  • The findings presented at ECTRIMS-ACTRIMS demonstrate that MAVENCLAD produced sustained reductions in serum NfL without continuous immunosuppression."
  • In a separate study out of Latin America, data was analyzed from 1,421 patients who received at least one course of cladribine tablets.
  • Over time, an increasing trend in treatment initiation among treatment-naïve patients was observed, suggesting an advantage of early utilization of cladribine treatment.

Precision Medicine and Alzheimer's Disease: Overcoming Biomarker Testing Barriers for Alzheimer's Disease Patients, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 13, 2023

TORONTO, Sept. 13, 2023 /PRNewswire-PRWeb/ -- Advances in biomarker testing are revolutionizing strategies for diagnosing and managing neurological disorders and shifting the current treatment paradigm to a more personalized approach.

Key Points: 
  • The featured speakers will review key barriers to clinical adoption of MCI and early AD-related biomarker testing.
  • Learn about what steps can be taken to overcome these testing barriers and optimize availability and access to testing.
  • This expert panel featuring Pete Riccelli, PhD, Senior Director, Precision Medicine, Commercial Strategy and Market Access, Veranex ; Catheline Plaideau, PhD, Sr.
  • Register for the live webinar taking place on Tuesday, October 3, 2023, at 12pm EDT (11am CDT) to learn how to identify and overcome challenges in Alzheimer's disease biomarker testing.

Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?

Retrieved on: 
Tuesday, August 1, 2023

The most recent report (n=102 US based neurologists) shows that what motivates neurologists’ prescribing is efficacy in both minimizing relapses and delaying disability progression.

Key Points: 
  • The most recent report (n=102 US based neurologists) shows that what motivates neurologists’ prescribing is efficacy in both minimizing relapses and delaying disability progression.
  • Other drivers of brand choice from the past, such as patient support services, do not appear to be major considerations of first therapy choice today.
  • Beyond understanding evolving treatment patterns and challenges, the RealTime Dynamix™ study also evaluated neurologists’ expectations for products in development.
  • Breaking into the RMS market will certainly not be easy, so deep market insights will be key along with outstanding clinical data.

Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Retrieved on: 
Tuesday, June 27, 2023

INDIANAPOLIS, June 27, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Key Points: 
  • INDIANAPOLIS, June 27, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance.
  • "An early and accurate diagnosis can help patients, caregivers and physicians determine a path forward, and the Elecsys CSF assays support diagnosis at early disease stages, when treatment is most effective."
  • In addition, evaluating both amyloid and tau Alzheimer's biomarkers using PET requires multiple appointments and procedures, and increases radiation exposure.
  • Roche's Elecsys AD CSF assays are already registered in 46 countries worldwide, including those accepting the CE mark.